Terns Pharma Q1 net loss $13.8M; cash $151.3M; pipeline prioritization extends runway into 2025

Terns Pharmaceuticals, Inc.

2023-Q1 EPS reported -$0.55

Net loss of $13.8M ($0.55 per share) vs $13.3M in Q1 2021; R&D $8.1M, G&A $5.7M.
Cash and equivalents $151.3M, expected to fund operations into 2025 with three clinical readouts.
IND opened for NASH Phase 2a trial of TERN-501 (mono + combo with TERN-101); top-line data expected H2 2023.
TERN-601 (oral GLP-1) IND-enabling underway; Phase 1 for obesity expected in 2023.
Partner Hansoh initiated Phase 1 trial of TERN-701 in CML in China; dosing underway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.